Timo Soeterik

52 CHAPTER 3 TABLE 3. Risk of metastasis due to low intensity monitoring per risk group Follow-up Patients who developed metastasized PCa during AS (%) p OR (95% CI) PSA PRIAS-eligible ( N = 495) Discordant PSA monitoring a 2/104 (2) 0.611 2.39 (0.42 – 13.50) Concordant PSA monitoring 4/391 (1) PRIAS-ineligible ( N = 463) Discordant PSA monitoring 5/148 (3) 0.037 5.25 (1.02 – 27.10) Concordant PSA monitoring 2/315 (1) Biopsy PRIAS-eligible ( N = 481) Discordant repeat biopsy testing 2/210 (1) 0.701 0.36 (0.06 – 2.08) Concordant repeat b biopsy testing 4/271 (2) PRIAS-ineligible ( N = 431) Discordant repeat biopsy testing 3/229 (1) 0.711 0.32 (0.07 – 1.51) Concordant repeat biopsy testing 4/202 (2) Overall PRIAS-eligible ( N = 495) Overall discordant c follow-up 2/257 (1) 0.434 0.30 (0.05 – 1.69) Overall concordant follow-up 4/238 (2) PRIAS-ineligible ( N = 463) Overall discordant follow-up 7/286 (2) 0.047 32.9 (0.02 – 51163) Overall concordant follow-up 0/177 (0) a Patients underwent ≥75% of recommended PSA tests according to the PRIAS protocol given their AS duration. b Patients underwent all scheduled repeat biopsies given their AS duration. c Patients underwent PRIAS concordant PSA monitoring as well as concordant repeat biopsy testing.